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Major histocompatibility class (MHC) II molecules are essential for running adaptive immune
response. They are produced in the ER and targeted to late endosomes with the help of invariant
chain (Ii) trimers. Ii trimerization may be induced by the Ii TM domain. To enable mechanistic
and structural studies of MHC class II–Ii assembly, soluble forms of the complexes were expressed.
We show that Ii trimerizes in the absence of the transmembrane part, prior to binding of a/b chains.
The biochemical analysis supports the suggestion that the MHC class II–Ii complexes are not neces-
sarily trimers of trimers, but that the Ii trimer can also be occupied by one or two MHC class II
complexes.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The major histocompatibility class (MHC) II–invariant chain (Ii)
complexes are transmembrane glycoproteins that play a central
role in adaptive immunity [1,2]. They are synthesized in the endo-
plasmic reticulum (ER) where the nascent MHC class II a and b
chains associate with Ii trimers [3,4]. Once fully assembled, the
MHC class II–Ii complexes are transported to the late endosomal
compartments called MIIC of professional antigen presenting cells
(APCs) [5,6]. Here, Ii is degraded in a step-wise manner by the lyso-
somal cysteine proteases [7,8] resulting in the release of the active
MHC class II dimers. Ii consists of several distinct segments that
play speciﬁc roles in the assembly and cellular localization of
MHC class II complexes, including the N-terminal cytosolic tail
which contains signals for the delivery of MHC class II into the
endocytic route [9], a single transmembrane helix, a trimerisation
domain located at the luminal site of the protein and a short seg-
ment termed CLIP which associate with the MHC class II peptide
binding groove and prevents premature binding of antigenic pep-
tides [10]. Ii exists in two alternatively spliced forms, the p31
and p41 form, which differ by the insertion of a 64 amino acid long
domain in the p41 form of Ii [11]. This domain is a strong inhibitorchemical Societies. Published by E
istry, Molecular and Struc-
uction, Jozef Stefan Institute,
77 3984.of cysteine endopeptidases suggesting that the invariant chain
might regulate its own proteolytic processing [12,13].
The molecular mechanism of MHC class II a (DRA) and b (DRB)
chain and Ii association has been extensively studied for the past
decades, however the exact mechanism of their assembly still re-
mains unclear. The classic model of the MHC class II–Ii assembly
suggests that the Ii ﬁrst forms a trimer via its trimerisation domain.
This trimers then act as a chaperone-like scaffold for the assembly
of three a and b chain dimers that concurrently bind to the Ii
trimers forming a nonameric complex [14,15]. Recently, Koch
et al. challenged this concept by showing that association of Ii with
DRA alone precede the binding of DRB and that the Ii trimer can
bind only a single MHC class II ab dimer before leaving the ER
for transport into the endocytic route [16–18].
Several studies evaluated the importance of the transmembrane
(TM) region in the trimerisation of Ii. It was shown that the TM re-
gions of the Ii strongly self-associate as a trimer [19]. Destabiliza-
tion of this TM interaction prevented trimerisation of Ii and
assembly of the complexes [20]. These studies were performed
by mutations of highly conserved amino acid residues within the
Ii TM domain and do not fully support the role of the TM domain
in the assembly of the complexes.
To unambiguously address the role of the TM domain of the Ii in
the assembly of the MHC class II–Ii complexes, we produced solu-
ble complexes lacking the TM region. The analysis of the puriﬁed
MHC class II–Ii complexes lacking the TM regions showed that sol-
uble Ii still formed a trimer that associate with MHC class II a and blsevier B.V. All rights reserved.
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rapid puriﬁcation in quantities sufﬁcient for further biochemical
studies.
2. Materials and methods
2.1. Gene cloning and construction of the expression vectors
The truncatedMHCclass IIa and b chains (DDRAandDDRB) con-
taining the N-terminal signal sequence but without the C-terminal
TM and cytosolic domains were ampliﬁed from the full length DRA
and DRB cDNAs, using the following set of primers: 50CCCA
AAGCTTGCCACCATGGCCATAAGTGGAGTCCCT30 and 50CCCAGAATTCT
TACTCTGTAGTCT30 as a forward and reverse primers for DDRA and
50CCCAAAGCTTGCCACCATGGTGTGTCTGAAGCTCCCT30 and 50CCCA
GAATTCTTACTTGCTCTGTG CAGATTCAG30 as a forward and reverse
primers forDDRB. The underlined sequences correspond to theHin-
dIII (forward primers) and EcoRI (reverse primers) endonuclease
recognition site. The region presented in bold is a Kozak consensus
sequence. The PCR products were cloned into the pcDNA3 expres-
sion plasmid (Invitrogen). The human p31 and p41 forms of Ii
(Dp31Ii and Dp41Ii) without the cytoplasmic and TM regions were
PCR ampliﬁed using 50CCCAACCGGTCGGCTGGACAAACTGACAGT30
as a forward and 50CCCAGG TACCCATGGGGACTGGGCCCAGATC30
as a reverseprimers. Theunderlined regions representAgeI andKpnI
restrictions sites. The PCR products were cloned into the pHLsec
expression plasmid [21] in frame with the N-terminal H2-jb signal
sequence and the C-terminal His-tag.
2.2. Expression of truncated MHC class II – invariant chain complexes
HEK293 cells were maintained in DMEM medium supple-
mented with 4 mM L-glutamine and 10% fetal bovine serum in a
CO2 incubator at 37 C with 5% CO2.
For the small-scale transfection, the HEK293T and HEK293S
GnTl- cells were seeded in a 6-well cell culture plate and transfec-
ted with Lipofectamin (Invitrogen) according to the manufacturer’s
instructions. For large-scale expression the cells were seeded in
T150 ﬂasks and cultured in 25 ml medium. When the cells reached
60% conﬂuency, co-transfection using 25 kDa linear PEI (Poly-
sciences Inc.) was performed. Forty micrograms of individual plas-
mids containing cDNAs for DDRA, DDRB, or p41 form of DIi were
mixed in equimolar ratios in a 5 ml of serum-free DMEM. One hun-
dred and twenty micrograms of PEI was added to the mixture.
After 10 min of incubation at the room temperature the mixture
was added to the cells. After 4 h, the media was exchanged with
25 ml of DMEMwithout FBS and the cells were cultured for 3 days.
2.3. Puriﬁcation of MHC class II – invariant chain complexes
The conditioned medium from the HEK293T cells seeded in 20
T150 ﬂasks (approximately 500 ml) was collected and concen-
trated on the Amicon ultra ﬁltration device and dialyzed against
the 30 mM Tris, pH 7.5, 100 mM NaCl, 20 mM imidazol buffer
(binding buffer). The sample was applied to the 1 ml HiTrap IMAC
FF column (GE Healthcare) charged with Ni2+ at a ﬂow rate 1 ml/
min. The unbound proteins were washed with the 20 column vol-
umes of the binding buffer. The bound proteins were eluted with
the binding buffer containing 300 mM imidazol. The eluted com-
plexes were dialyzed against the 20 mM Tris, pH 7.5 buffer and
additionally puriﬁed on the Mono Q column (GE Healthcare) equil-
ibrated in the same buffer. The recombinant complexes were
eluted with a linear gradient of NaCl from 0 to 0.5 M in the
20 mM Tris buffer, pH 7.5. The eluted samples were desalted by
a PD-10 desalting column, concentrated and stored at 70 C.2.4. SDS–PAGE, Western blotting and N-terminal sequencing
The puriﬁed complexes were analyzed by SDS–PAGE using the
15% Bis–Tris gels and visualized by the Coomassie Brilliant Blue
staining. For Western blot analysis, the proteins were electro-
transferred to nitrocellulose membrane. The membrane was
blocked with 5% (w/v) skim milk in Tris-buffer saline containing
0.05% (v/v) Tween 20 (TBST) for one hour at room temperature.
The rabbit polyclonal anti-DRA, anti-DRB [5] and anti-Ii antibodies
(a gift from P. Cresswell, Yale University) were added in dilution
1:1000 and incubated for one hour at room temperature. The
bound antibodies were detected with the horseradish peroxidase
(HRP) conjugated goat anti-rabbit IgG and visualized with peroxi-
dase substrate.
For N-terminal sequencing, the proteins separated on SDS–
PAGE gel were electrotransfered to the PVDF membrane, and visu-
alized with 0.1% Brilliant Blue G in 1% (v/v) acetic acid and 40% (v/
v) methanol. The N-terminal sequencing was performed on Precise
Protein Sequencing System 492 (PE Applied Biosystems).
2.5. Co-Immunoprecipitation of the complexes
The IB5 mouse monoclonal antibody against the human DRA
or Tu36 mouse monoclonal antibody against DR dimers were
added to 1 ml of the conditioned medium and incubated for
one hour on the rotary wheel at 4 C. The antibody–protein com-
plex was isolated by protein A Sepharose beads (GE Healthcare)
according to the manufacturer’s instructions and analyzed by
Western blot using anti-DRA, anti-DRB and anti-Ii rabbit poly-
clonal antibodies.
2.6. Analytical size-exclusion chromatography
Superdex 200 HR 10/30 (GE Healthcare) size exclusion column
was equilibrated in 30 mM HEPES, pH 7.5, 0.3 M NaCl buffer and
calibrated with the gel ﬁltration standards (Bio-Rad). The Mr of
the complexes was determined from the plots of elution volumes
of standards versus log of their Mr.
2.7. Crosslinking of truncated MHC class II – invariant chain complexes
Ten micrograms of the D(DRA/DRB/p41Ii) complex or the
Dp41Ii alone in 20 ll of HEPES, pH 7.5 buffer were mixed with
2.5 ll of 2.3% solution of gluteraldehyde or 5 mg/ml solution of
DSS and incubated at the room temperature for 15 min. The cross-
linking reaction was terminated by addition of 5 ll of 1 M Tris, pH
7.5. The crosslinked complexes were separated on the 3–8% Tris–
Acetate PAGE gels and stained with Coomassie Blue.
2.8. Deglycosylation with Endo H
The samples were treated with endoglycosidase Endo H (New
England Biolabs, UK) according to the manufacturer’s instructions.
The samples were separated by SDS–PAGE and analyzed by Wes-
tern blotting using anti-DRB antibodies.
3. Results and discussion
3.1. Design of the expression constructs
To promote the expression of MHC class II–Ii chain complexes
in the soluble form, sequences of the individual chains have been
modiﬁed. In the case of Ii the N-terminal cytosolic tail and the
transmembrane region (encompassing amino acids from G47 to
Y72) followed by three consecutive Gln residues were removed.
AB
Fig. 1. Schematic representation of expression plasmids for (A) MHC class II associated p31 and p41 forms of the invariant chain (Ii) and (B) MHC class II a (DRA) and b (DRB)
chains. The regions of DRA, DRB and Ii that were cloned into the expression plasmids are annotated with D. SP marks the signal peptide, TM the transmembrane region,  the
sites of N-linked glycosylation and 6xHis the histidine afﬁnity tag.
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into the pHLSec plasmid in frame with the N-terminal H2-Kb signal
sequence (Fig. 1A). The truncated Ii lacks the N-terminal type II sig-
nal sequence essential for the delivery of the complexes into the
endocytic route and we therefore introduced a new type I signal
sequence for insertion in the ER and transport for secretion. In con-
trast to Ii, the transmembrane regions of MHC class II a and b
chains are located at the C-termini. They encompass residues from
N217 to I239 and from M228 to F250 of the a (DRA) and b (DRB)
chains respectively. To facilitate expression of the soluble DRA
and DRB chains both sequences were removed by terminating
the chains at amino acid E216 (DRA) and K227 (DRB), respectively.
Hence, only the luminal parts of DRA and DRB chains with the na-
tive N-terminal signal sequence were cloned into the pcDNA3 plas-
mid (Fig. 1B). All constructs contain the N-terminal signal
sequences that will target the synthesized polypeptide chains into
the lumen of ER, where the assembly of the complexes takes place.
3.2. Association of soluble MHC class II ab and Ii in vivo
Individual constructs of the truncated DDRA, DDRB and DIi
chains were transfected in HEK293 cells either alone or mixed in
different combinations. Expression of individual chains was ana-
lyzed by immunoblotting (Fig. 2). When the p41 and p31 isoforms
of theDIi were transfected alone or in combination withDDRA and
DDRB chains the majority of the invariant chain was secreted
(Fig. 2, Anti Ii blots). The absence of the cytosolic targeting signals
thus resulted in targeting of the Ii into the secretory pathway [22].
In contrast to the DIi, a different distribution pattern was observed
when expression of DDRA and DDRB chains was analyzed. When
DDRA chain was transfected alone or in combination of only one
of the other subunits (DDRB chain or the DIi), it was only detected
inside the cells, whereas expression of all three subunits (the
DDRA, DDRB and DIi chains) resulted in secretion as detected by
anti-DRA antibodies (Fig. 2, Anti DR blot). Similar results were ob-
tained for DDRB. The secreted DRB was detected only when DDRB
was co-transfected together with DDRA and the DIi (Fig. 2, AntiDRB blot). When transfected alone or only with the DIi or DDRA,
the DDRB chain was retained and detected only intracellularly.
Due to the weak afﬁnity and high cross reactivity of DRB antibod-
ies, the intracellular expression of DDRB could be detected only by
increasing the exposure time for blot development which resulted
in the increased background and non-speciﬁc staining of other pro-
teins. However, from Fig. 2, (Anti DRB blot) it can be clearly seen
that DDRB, when expressed alone or in combination with DDRA or
DIi, is retained intracellularly. We have also observed increased
intracellular expression of DDRA as well as DDRB when transfec-
ted with DIi alone (Fig. 2, blot Anti DRA and blot Anti DRB), sug-
gesting that DIi somehow stabilize individual DRA and DRB.
Comparison of DDRA, DDRB chains and the DIi inside the cells
and secreted forms shows obvious differences in molecular weight.
Since all three chains contain a number of N-glycans (Table 1), the
deviation in the molecular weight marks conversion of high-man-
nose to complex N-glycans that is the result of transport through
the secretory pathway. This also indicates that DDRA and DDRB
when transfected alone or only in pairs are retained in the ER. To
provide further support that the differences in the molecular
weight arise from the localization and N-glycosylation pattern,
we have analyzed DDRB transfected into the HEK293S GnTl- cell
line which is deﬁcient in N-acetylglucosaminyltransferase I activity
and therefore lacks complex type N-glycans. When DDRB was
cotransfected with DDRA and the DIi in HEK293S GnTl- cells, the
apparent molecular weight of the secreted DDRB is identical to
the molecular weight of the intracellularly accumulated DDRB
(Fig. 3A). The weight of intracellular DDRB was further decreased
by the Endo H treatment, which removes the basic mannose glycan
attached to the proteins in the ER during early stages of their syn-
thesis, whereas secreted DDRB (when cotransfected with DDRA
and DIi) is Endo H resistant. The ER localization of DDRB, when
transfected alone, was additionally conﬁrmed by staining ﬁxed
cells with anti-DRB antibodies before analyses by confocal micros-
copy (Fig. 3B). Also DDRA was retained in the ER according to bio-
chemical and microscopy criteria. These observations are
consistent with the previous reports that MHC class II dimers can
Fig. 2. Expression analysis of soluble MHC class II and Ii proteins. Western blot analysis of intra- (C) and extracellular (M) expression ofDp41Ii,Dp31Ii,DDRA and DDRB after
transfection of HEK293T cells with different combinations of plasmids. The proteins were detected using the anti-Ii, anti-DRA and anti-DRB antibodies. Plus (+) and minus ()
signs indicate which combination of plasmids was used in the transfection experiments. The anti-DRB blot developed with extended exposure time is marked with .
Table 1
Calculated molecular weights and number of potential N-glycosylation sites of
truncated forms of MHC class II DRA and DRB and p41 invariant chain.
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and DRB chains are retained in the ER [15,23].
The existence of the complex between secreted DDRA, DDRB
and the DIi was veriﬁed by immunoprecipitation using Tu36
mouse monoclonal antibody that recognizes only properly folded
and loaded MHC class II DR dimers and the 1B5 mouse monoclonal
antibody recognizing DRA [5]. Immunoblots of immuno-isolated
fractions using anti-DRA, DRB and Ii antibodies showed that all
three chains associated in a complex (Fig. 4).
3.3. Large-scale expression and puriﬁcation of soluble MHC class II – Ii
invariant chain complexes
The MHC class II–Ii complexes secreted from HEK293T and gly-
cosylation defective HEK293S GnTl- cell lines were puriﬁed on the
Ni-chelating column. We have attached a His-tag at the C-terminus
of Ii for isolation purposes. Co-puriﬁed DDRA and DDRB should
then be in a complex with DIi. To separate the soluble MHC class
II–Ii chain complexes from the soluble Ii alone that might co-purify
on the Ni-afﬁnity column, the samples were subjected to furtherpuriﬁcation. The calculated isoelectric points for the truncated
MHC class II–Ii complex and the Ii are 5.71 and 8.05, respectively
which suggest that they can be separated by ion-exchange chro-
matography (Mono-Q) performed at pH 7.5. At this pH, the com-
plex is negatively charged and should bind to the positively
charged ion-exchange carrier, whereas the more acidic empty Ii
trimer should theoretically ﬂow through. The fractions corre-
sponding to the major eluted peak from the Mono-Q column were
collected and analyzed by SDS–PAGE (Fig. 5A). The positions of
DDRA, DDRB and DIi on the PAGE-gel were identiﬁed by combin-
ing the results of the Western blot analysis and the N-terminal
amino acid sequencing. The N-terminal sequences conﬁrmed the
presence of all three chains in the sample (Fig. 5B).
The molecular weights of DDRB – as deduced from SDS–PAGE
analysis – corresponded to the theoretical masses (including the
carbohydrates) calculated from the amino acid sequences (Table 1).
The estimated molecular weight for DDRA is higher than calcu-
lated, however expression in HEK293S GnTl- cells results in the
formation of a sharp band at 30 kDa (estimated Mw). The apparent
weight of the glycosylated p41 form of DIi is between 35 and
40 kDa, which is substantially higher than the theoretical value.
Expression of the complexes in N-glycosylation deﬁcient cell line
resulted in the decrease of the molecular weight of the Ii, however,
the Ii is still present in several bands with higher weight than ex-
pected. The single O-glycosylation site in the Ii that contributes a
considerable number of negative charges may cause the faster
migration by SDS–PAGE. Immunoblot analysis of the puriﬁed com-
plexes using anti-His antibodies, which recognize the afﬁnity tag
attached to the C-terminus of the Ii, showed identical staining as
Coomassie Blue. By the N-terminal sequencing, we were able to
identify only a single amino acid sequence that starts at the last
three amino acids of the H2-jb signal sequence followed by the
AB
Fig. 3. Analysis of the molecular size, cellular localization and glycosylation pattern of DDRB. (A) DDRB was transfected together with DDRA and the DIi in HEK293T and
HEK293S GnTl- cells and analyzed by anti-DRB immunobloting. C and M annotates intracellular and extracellular expression. Intracellular and secreted DDRB was
additionally treated with Endo H. (B) Immunoﬂuorescence staining of DDRB transfected alone in HEK293T cells and imaged by confocal microscopy. The arrow indicates the
accumulation of the DDRB inside the ER. Bar: 100 lm.
Fig. 4. Secreted MHC class II molecules lacking the transmembrane region associate with the soluble Ii. Western blot analysis of immunoprecipitated soluble MHC class II–Ii
complexes is shown. The complexes were immunoprecipitated with Tu36 and 1B5 mouse monoclonal antibodies. The individual chains of the complex were detected with
the rabbit polyclonal antibodies speciﬁc to individual chain.
A B
Fig. 5. SDS–PAGE analysis and N-terminal amino acid sequencing of MHC class II–Ii chain complexes. (A) The purity of the complexes expressed in HEK293T (lane 1) and
HEK293S GnTl- cell line (lane 2) was analyzed by SDS–PAGE. The positions of DDRA, DDRB and the Dp41Ii are marked. (B) The complex puriﬁed from cotransfected HEK293T
cells was transferred to PVDF membrane. The bands that were cut out and sequenced are shown in frames. The determined N-terminal amino acid sequences are shown in
red. The predicted cleavage sites for signal peptidase are marked with arrows.
1322 D. Majera et al. / FEBS Letters 586 (2012) 1318–1324Ii sequence. This further indicates that multiple and diffused bands
corresponding to the p41 Ii form of the invariant chain are the con-sequence of posttranslational modiﬁcations and not of proteolytic
degradation. The N-terminal sequence was also determined for
D. Majera et al. / FEBS Letters 586 (2012) 1318–1324 1323DDRA and DDRB. In both cases the sequence matched the se-
quences of DRA and DRB lacking the signal peptide (Fig. 5b).
3.4. Oligomeric state of soluble MHC class II–Ii complexes
To analyze the stoichiometry of the expressed proteins, we as-
sessed the molecular weight of puriﬁed proteins by analytical size
exclusion chromatography and crosslinking experiments. The puri-
ﬁed proteins eluted from the Superdex 200 HR size exclusion col-
umn in a single symmetric peak with elution volume around 10 ml
(Fig. 6A). The apparent molecular weight of these complexes was
determined from the calibration curve obtained by plotting the
elution volumes of the protein standards versus logarithm of their
molecular weight (Fig. 6B). The elution volumes of the DDRA-
DRBp41Ii complexes puriﬁed from HEK293T and HEK293S GnTl-
cell lines correspond to the apparent molecular weights of 290
and 273 kDa. Since only a single peak was eluted from the size-
exclusion column these results suggest that the expressed DDRA,
DDRB and the DIi associate in high-molecular weight complex.
(It should be noted that the estimation of molecular weight of pro-
teins by size exclusion chromatography is reliable only for globular
proteins as it depends on the protein radius and its hydrodynamic
properties and should therefore be considered only as an approxi-
mation of the actual weight.)
To independently conﬁrm the oligomeric structure of the solu-
ble MHC class II–p41Ii complex, the puriﬁed complex was cross-
linked with gluteraldehyde and DSS. Both crosslinkers gave the
same results so only data with gluteraldehyde are shown (Fig. 7).
To reduce the unspeciﬁc crosslinking between complexes, the con-
centration of the protein used in these experiments was reduced
below 0.5 mg/ml. The molecular weight of the cross-linked soluble
p41Ii is 100 and 75 kDa for glycosylated and non-glycosylated
forms of the protein. This weight is in agreement with the expected
molecular weight of the Ii trimers. Since the trimeric structure was
formed in the absence of the transmembrane and cytosolic parts of
the Ii, it is evident that the transmembrane region and cytosolic tail
of Ii are not critical for the formation of the nonameric complex.
The luminal segment of Ii should also contain information that in-
duces trimerization. The crosslinking of the D(DRADRBp41Ii) com-
plexes showed two major bands of molecular mass of 130 andFig. 6. Assessment of molecular weight of MHC class II–41Ii complexes using size excl
complexes expressed in HEK293T (blue) and HEK293S GnTl- cells (red). The elution proﬁl
44 kDa, myoglobin 17 kDa and vitamin B12 1.35 kDa) is shown in gray. (B) Calibration p
weight. The elution volume and calculated molecular weight for MHC class II–p41Ii com180 kDa for glycosylated form of the complexes, and two bands
of 110–140 kDa for underglycosylated forms of the complexes.
However, a minor bands of 210 and 170 kDa were also observed.
A protein complex of 209 kDa would correspond to the calculated
molecular weight of the expected (DRA–DRB–Ii)3 nonameric form.
The results from the cross-linking experiments suggest consider-
able heterogeneity in the binding of HLA–DRAB complexes on
the Ii trimer with a preference for one and two MHC class II com-
plexes corresponding to molecular weights of 120 and 160 kDa,
respectively (Table 1).
With two independent experiment approaches, namely size-
exclusion chromatography and crosslinking, we have estimated
the composition of secreted MHC class II–Ii protein complexes.
The size exclusion experiments suggest that the complex resem-
bles a trimer of trimers with three MHC class II complexes asso-
ciated to three Ii chains that form the core of the complex.
Chemical cross-linking and more precise molecular weight deter-
mination by SDS–PAGE reveals a more complex picture with an Ii
trimer associated with mainly one or two MHC class II complexes
and only a small proportion in the nonameric state. This would
correspond to the recent observations Koch and coworkers [18],
who suggested that the stoichiometry of the MHC class II–Ii chain
composition may not be a trimer of trimers (a DRA–DRB–Ii tri-
mer) [3] but a pentamer composed of a trimer of Ii with a one
pair of D (DRADRB) bound. As Ii is present in the ER in consider-
ably higher amounts than DRA and DRB chains, two options exist.
MHC class II-Ii complexes are only considered correctly folded to
leave the ER when in a nonameric complex (the trimer of trimers)
or the Ii trimer can leave the ER when already one or two MHC
class II complexes are associated. Our results suggest that the lat-
ter option is most likely. The ratio between fully and partially
MHC class II–Ii loaded complexes may depend on the relative
amounts of Ii and MHC class II DRA and DRB expressed, which
may vary between cells and likely depending on the DRA and
DRB sequences. The existence of intermediate MHC class II–Ii
complexes of various stoichiometries was also observed before.
Jasanoff et al. showed that under in vitro conditions MHC class
II dimers bind to the Ii trimmers independently and that
nonameric complexes are formed only in the excess of MHC class
II dimmers [24].usion chromatography. (A) Superdex 200 HR elution proﬁles of MHC class II–p41Ii
e of protein standards (thyroglobulin 667 kDa, gamma-globulin 158 kDa, ovalbumin
lot obtained from plotting the elution volume of standards versus their molecular
plexes are marked.
Fig. 7. Crosslinking of the soluble MHC class–p41Ii and p41Ii complexes. The lanes with the gluteraldehyde (Glu) crosslinked material are marked on the top with ‘‘+’’ and the
lanes without crosslinking with ‘‘’’. The proteins were separated on 3–8% Tris–Acetate gels and stained with Coomassie Blue.
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Several studies that were addressing the role of Ii TM region in
the trimerisation of Ii and assembly of MHC class II–Ii complexes
suggested that this domain plays an essential role in these pro-
cesses [19]. These studies utilized point mutations in the highly
conserved patch of polar amino acids in the TM domain of the Ii.
These mutations possibly disrupted the interaction between the
transmembrane helices of Ii, which might disturb the orientation
of Ii in the luminal domain to prevent trimerisation and binding
of MHC class II dimers. Here we analyzed the assembly and oligo-
meric state of the Ii and MHC class II complexes lacking the trans-
membrane region. We have shown by in vivo and in vitro analysis
that the Ii chain lacking the transmembrane and cytoplasmic re-
gions is efﬁciently secreted as a trimer. Moreover, we have shown
that soluble Ii can assemble and be secreted with soluble DRA and
DRB in complexes that may be more heterogeneous than assumed
previously.
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